Bispecific ADCs or multi-specific ADCs, alongside other innovative designs, seek to overcome these hurdles by integrating extra targeting mechanisms and functionality. Beyond novel ADC designs ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Radiance's current oncology pipeline includes RB-201, a bispecific HER2xTROP2 ADC for solid tumors. For more information on Radiance visit www.radiancebiopharma.com. CSPC is a leading ...

ADC Therapeutics SA (NYSE ... trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory ...

with comparable response rates in patients previously treated with an ADC and/or CAR-T." Teclistamab, meanwhile, is a companion bispecific to Janssen's GPRC5DxCD3 drug talquetamab, which has also ...

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated ... GlaxoSmithKline's first-to-market antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin).

Innate Pharma SA (IPHA) announced that the FDA has granted Breakthrough Therapy Designation to lacutamab for treating adults ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which ...